300765 CSPC Innovation Pharmaceutical
- 30.34
- -0.96-3.07%
CSPC Innovation Pharmaceutical News
CSPC Innovation Pharmaceutical (300765.SZ) spent a total of 91,129,600 yuan to repurchase 0.23% of its shares.
CSPC Innovation Pharmaceutical (300765.SZ) announced that, as of May 31, 2024, the company repurchased 3,177,200 shares of its own stock through a stock repurchase dedicated securities account by means of centralized competitive bidding trading, accounting for 0.23% of the company's current total share capital. The highest fill price was 34.99 yuan/share, and the lowest fill price was 18.68 yuan/share. The total amount paid was 911,296,433.35 yuan (excluding transaction fees).
The Total Return for CSPC Innovation Pharmaceutical (SZSE:300765) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are hard to find, but they can generate massive returns over long periods. To wit,
New Novus (300765.SZ): A total cost of 39.2313 million yuan to buy back 1.488,200 shares
On May 7, GLONGHUI (300765.SZ) announced that as of April 30, 2024, the company had repurchased 1.488,200 shares of the company's shares through a special stock repurchase securities account, accounting for 0.11% of the company's current total share capital. The highest transaction price was 34.99 yuan/share, the minimum transaction price was 18.68 yuan/share, and the total amount paid was 39.2313 million yuan (excluding transaction fees).
CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at CSPC Innovation Pharmaceutical's (SZSE:300765) recent performance, when its stock has declined 7.0% over the past month. However, a closer look at its soun
New Novus (300765.SZ): Net profit of 79.0613 million yuan in the first quarter decreased by 38.86% year on year
On April 22, GLONGHUI (300765.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 524 million yuan, down 27.08% year on year; net profit attributable to shareholders of listed companies was 79.0613 million yuan, down 38.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 78.171,5 million yuan, down 56.44% year on year; basic earnings per share were 0.0676 yuan.
New Novus (300765.SZ) plans to transfer 10 shares and increase 2 shares to pay 3.2 yuan before interest deduction on April 25
New Novus (300765.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
New Novus (300765.SZ): Medication Clinical Trial Approval Notice for Obtaining Antibody Drug Conjugate (ADC) SYS6023
On March 20, GLONGHUI (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” on the antibody drug conjugate (ADC) SYS6023 and will conduct clinical trials in the near future. SYS6023 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, releases toxins, and kills tumor cells. This product is classified as a therapeutic biological product category 1
CSPC Innovation Pharmaceutical's Attributable Profit Rises 4%; Shares Jump 6%
CSPC Innovation Pharmaceutical's (SHE:300765) attributable profit rose 4.03% to 755.6 million yuan in 2023 from 726.3 million yuan in 2022, according to a Friday filing with the Shenzhen bourse. Earni
CSPC Group: New Novi's annual net profit of 756 million yuan increased 4.03% year-on-year
Shiyao Group (01093) announced the results of its subsidiary Xinover (300765.SZ) for the year ended December 31, 2023. The group achieved operating income of 2,502 billion yuan (RMB, same below) during the period, a year-on-year decrease of 4.75%; net profit to mother of 756 million yuan, an increase of 4.03%; and basic income per share of 0.6533 yuan.
CSPC Group (01093): New Novartis (300765.SZ)'s annual net profit of 756 million yuan increased 4.03% year-on-year
CSPC Group (01093) announced the subsidiary Novell (300765.SZ) as of December 31, 2023...
New Novus (300765.SZ): Net profit for 2023 increased 4.03% to 756 million yuan, plans to convert 10 to 2 to 3.2 yuan
Glonghui, March 14 | New Novartis (300765.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,502 billion yuan, a year-on-year decrease of 4.75%; net profit attributable to shareholders of listed companies was 756 million yuan, up 4.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 744 million yuan, up 13.09% year on year; basic income per share was 0.6533 yuan; and distributed to all shareholders a cash dividend of 3.2 yuan (tax included) for every 10 shares of the capital reserve 2 additional shares.
New Novus (300765.SZ): A total cost of 357.3898 million yuan to buy back 1.3852 million shares
On March 4, GLONGHUI (300765.SZ) announced that as of February 29, 2024, the company had repurchased 1.385,200 shares of the company's shares through a special stock repurchase securities account, accounting for 0.12% of the company's current total share capital. The highest transaction price was 34.99 yuan/share, the minimum transaction price was 18.68 yuan/share, and the total amount paid was 357.3898 million yuan (excluding transaction fees).
New Novus (300765.SZ) adjusted the maximum price limit for repurchasing the company's shares to no more than 38 yuan/share
According to Zhitong Finance App, Xinnovo (300765.SZ) announced that the company plans to adjust the maximum repurchase price from no more than RMB 26.11 per share (inclusive) to no more than RMB 38.00 per share (inclusive) (the adjusted upper limit of the repurchase price did not exceed 150% of the average trading price of the company's shares on the 30 trading days before the board of directors passed the resolution to adjust the maximum share repurchase price). Other than adjusting the upper limit of the share repurchase price, there have been no changes to the other elements of this share repurchase plan.
New Novus (300765.SZ): cumulative repurchases of 220,000 shares
On February 2, GLONGHUI (300765.SZ) announced that as of January 31, 2024, the company had repurchased 220,300 shares of the company's shares through a special stock repurchase securities account, accounting for 0.02% of the company's current total share capital. The highest transaction price was 25.14 yuan/share, the lowest transaction price was 18.68 yuan/share, and the total amount paid was 4,247,354 yuan.
New Novus (300765.SZ): The current work will mainly focus on R&D/clinical development in the research pipeline
On January 26, 2024, GLONGHUI (300765.SZ) held an online conference call on January 25, 2024. Regarding “Prospects for the future revenue scale of New Novus,” the company replied that due to the current restructuring process, affected by many factors such as the completion of the restructuring, it is not yet possible to predict the relevant revenue with a high degree of accuracy. Currently, the work will mainly focus on R&D/clinical development in the research pipeline. For example, EGFR-ADC and RSV vaccines, key products in the R&D pipeline, need to speed up research and development progress, strive for early approval, and contribute revenue.
Shareholders Should Be Pleased With CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) Price
With a price-to-earnings (or "P/E") ratio of 46.7x CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) may be sending very bearish signals at the moment, given that almost half of all companies in
CSPC Baike's 2023 Profit Reaches 859 Million Yuan
CSPC Baike (Shandong) Biopharmaceutical's net profit hit 859 million yuan in 2023, while revenue reached 4.72 billion yuan, according to information released Wednesday. CSPC Baike is a company in char
New Novus (300765.SZ): Plans to purchase 100% of the shares of Shijiao 100 grams to further extend the biomedical layout to cutting-edge fields such as long-lasting proteins, and resume trading tomorrow
On January 24, GLONGHUI (300765.SZ) announced plans to issue shares and pay cash to purchase assets and raise supporting capital and related transactions. The listed company plans to purchase 100% of the shares of Shijiao Baig held by Vitamin Pharmaceuticals, Shijiao Shanghai, and Enbipu Pharmaceutical by issuing shares and paying cash. The cash payment ratio in this transaction did not exceed 10%, and the rest was paid by issuing shares. The specific share and cash payment ratios will be negotiated by the parties based on the final transaction price of the underlying asset and disclosed in the restructuring report. After the transaction is completed, the listed company will hold 100 grams of Shiyao
New Novus (300765.SZ): Plans to issue shares and pay cash to buy assets and raise supporting capital, and suspends stock trading
On January 10, GLONGHUI (300765.SZ) announced that the company is planning to issue shares and pay cash to purchase assets and raise supporting capital and related transactions. This transaction is expected to constitute a major asset restructuring and not a restructuring listing. Due to uncertainties about related matters, in order to protect investors' interests and avoid a significant impact on the company's stock price, trading of the company's shares began to be suspended after the opening of the market on January 11, 2024 after applying to the Shenzhen Stock Exchange in accordance with the relevant regulations of the Shenzhen Stock Exchange. The target asset of this transaction is CSPC Group Baike (Shandong) Biopharmaceutical Co., Ltd.
New Novus (300765.SZ): The company has not yet laid out the field of blood products
Gelonghui, January 4: An investor asked New Novell (300765.SZ) through an interactive platform: Dear Director, Hello! May I ask if your company and the newly funded Jushi Biotech Company have already deployed the blood products sector? Thanks for the answers! New Novus (300765.SZ) replied: The company has not yet laid out the blood products field.
Analysis
Price Target
No Data
